# Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

> **NCT03761914** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sellas Life Sciences Group** · enrollment: 26 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Ovarian Cancer
- Colorectal Cancer
- Triple-negative Breast Cancer
- Small-cell Lung Cancer

## Interventions

- **BIOLOGICAL:** galinpepimut-S
- **BIOLOGICAL:** pembrolizumab
- **OTHER:** Montanide
- **BIOLOGICAL:** GM-CSF

## Key facts

- **NCT ID:** NCT03761914
- **Lead sponsor:** Sellas Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-30
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-10-27
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761914, "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03761914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*